多年来，测序技术和质谱技术一直以各自独特的文化和专业知识发展，互相孤立。这两种技术对于检查分子表型在中心法则下的互补方面至关重要。综合多组学努力在不同领域之间架起分析鸿沟，以完成更全面的生命事件和疾病机制。蛋白质基因组学是一个综合多组学领域。在这篇综述中，我们主要总结和讨论三个方面：蛋白质基因组学的工作流程、蛋白质基因组学在癌症研究中的应用以及蛋白质基因组学在癌症研究中的SWOT（优势、弱势、机会、威胁）分析。总之，蛋白质基因组学在阐明许多未注释基因异常或非经典变体的功能后果、鉴定驱动基因和新颖治疗靶点方面具有广阔的前景，这将大幅加快精准肿瘤学的发展。

For years, the paths of sequencing technologies and mass spectrometry have occurred in isolation, with each developing its own unique culture and expertise. These two technologies are crucial for inspecting complementary aspects of the molecular phenotype across the central dogma. Integrative multiomics strives to bridge the analysis gap among different fields to complete more comprehensive mechanisms of life events and diseases. Proteogenomics is one integrated multiomics field. Here in this review, we mainly summarize and discuss three aspects: workflow of proteogenomics, proteogenomics applications in cancer research, and the SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis of proteogenomics in cancer research. In conclusion, proteogenomics has a promising future as it clarifies the functional consequences of many unannotated genomic abnormalities or noncanonical variants and identifies driver genes and novel therapeutic targets across cancers, which would substantially accelerate the development of precision oncology.